Pharmacogenetics of CYP1A2 activity and inducibility in smokers and exsmokers

Pharmacogenetics and Genomics

Volumn 23, Issue 5, 2013, Pages 286-292

  Dobrinas, Maria ^a   Cornuz, Jacques ^b   Eap, Chin B ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

CYP1A2; genetic polymorphism; inducibility; nuclear receptors; smoking

Indexed keywords

CAFFEINE; CYTOCHROME P450 1A2; PARAXANTHINE;

ARTICLE; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; GENOTYPE; HUMAN; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SMOKING CESSATION;

EID: 84876288069     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283602e75     Document Type: Article

References (37)

1. Zhou SF, Wang B, Yang LP, Liu JP. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev 2010; 42:268-354.
2. Kroon LA. Drug interactions with smoking. Am J Health Syst Pharm 2007; 64:1917-1921. (Pubitemid 47462906)
3. Gunes ADahl ML. Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics 2008; 9:625-637. (Pubitemid 351803920)
4. Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why how, and when? Basic Clin Pharmacol Toxicol 2005; 97: 125-134. (Pubitemid 41291208)
5. Eap CB, Bender S, Jaquenoud Sirot E, Cucchia G, Jonzier-Perey M, Baumann P, et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of the CYP1A2 gene. J Clin Psychopharmacol 2004; 24:214-219. (Pubitemid 38380846)
6. Carrillo JA, Herraiz AG, Ramos SI, Gervasini G, Vizcaino S, Benitez J. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 2003; 23:119-127. (Pubitemid 36368788)
7. Bondolfi G, Morel F, Crettol S, Rachid F, Baumann P, Eap CB. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit 2005; 27:539-543. (Pubitemid 41098833)
8. Dobrinas M, Cornuz J, Oneda B, Kohler Serra M, Puhl M, Eap CB. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharmacol Ther 2011; 90:117-125.
9. Gunes A, Ozbey G, Vural EH, Uluoglu C, Scordo MG, Zengil H, et al. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. Pharmacogenomics 2009; 10: 769-778.
10. Ghotbi R, Christensen M, Roh HK, Ingelman-Sundberg M, Aklillu E, Bertilsson L. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 2007; 63:537-546. (Pubitemid 46684487)
11. Dobrinas M, Cornuz J, Pedrido L, Eap CB. Influence of cytochrome P450 oxidoreductase (POR) genetic polymorphisms on CYP1A2 activity and inducibility by smoking. Pharmacogenet Genomics 2012; 22: 143-151.
12. Jiang Z, Dalton TP, Jin L, Wang B, Tsuneoka Y, Shertzer HG, et al. Toward the evaluation of function in genetic variability: characterizing human SNP frequencies and establishing BAC-transgenic mice carrying the human CYP1A1 CYP1A2 locus. Hum Mutat 2005; 25:196-206. (Pubitemid 40216616)
13. MacLeod S, Sinha R, Kadlubar FF, Lang NP. Polymorphisms of CYP1A1 and GSTM1 influence the in vivo function of CYP1A2. Mutat Res 1997; 376:135-142. (Pubitemid 27248596)
14. Jiang Z, Dragin N, Jorge-Nebert LF, Martin MV, Guengerich FP, Aklillu E, et al. Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet Genomics 2006; 16: 359-367.
15. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 2004; 279:23847-23850. (Pubitemid 38725238)
16. Harper PA, Wong JY, Lam MS, Okey AB. Polymorphisms in the human AH receptor. Chem Biol Interact 2002; 141:161-187. (Pubitemid 35223210)
17. Vieta E, Owen A, Baudelet C, McQuade RD, Sanchez R, Marcus RN. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study. Curr Med Res Opin 2010; 26: 1485-1496.
18. Okey AB, Boutros PC, Harper PA. Polymorphisms of human nuclear receptors that control expression of drug-metabolizing enzymes. Pharmacogenet Genomics 2005; 15:371-379. (Pubitemid 40835077)
19. Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, Kliewer SA. Nuclear pregnane X receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 2002; 62:462-469.
20. Yoshinari K, Yoda N, Toriyabe T, Yamazoe Y. Constitutive androstane receptor transcriptionally activates human CYP1A1 and CYP1A2 genes through a common regulatory element in the 50-flanking region. Biochem Pharmacol 2010; 79:261-269.
21. Narvaez MJ, Anderson GR, Pickwell GV, Quattrochi LC. Characterization of adjacent E-box and nuclear factor 1-like DNA binding sequence in the human CYP1A2 promoter. J Biochem Mol Toxicol 2005; 19:78-86. (Pubitemid 40571688)
22. Martinez-Jimenez CP, Castell JV, Gomez-Lechon MJ, Jover R. Transcriptional activation of CYP2C9, CYP1A1, and CYP1A2 by hepatocyte nuclear factor 4alpha requires coactivators peroxisomal proliferator activated receptorgamma coactivator 1alpha and steroid receptor coactivator 1. Mol Pharmacol 2006; 70:1681-1692.
23. Crawford JH, Yang S, Zhou M, Simms HH, Wang P. Down-regulation of hepatic CYP1A2 plays an important role in inflammatory responses in sepsis. Crit Care Med 2004; 32:502-508. (Pubitemid 38234132)
24. Zhou M, Maitra SR, Wang P. The potential role of transcription factor aryl hydrocarbon receptor in downregulation of hepatic cytochrome P-450 during sepsis. Int J Mol Med 2008; 21:423-428. (Pubitemid 351802636)
25. Klein K, Winter S, Turpeinen M, Schwab M, Zanger UM. Pathway-targeted pharmacogenomics of CYP1A2 in human liver. Front Pharmacol 2010; 1: 1-20.
26. Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 1994; 4:109-116. (Pubitemid 24210928)
27. R: a language and environment for statistical computing, 2010, R Foundation for Statistical Computing,Vienna, Austria. Available at: http://www.R-project.org [Accessed 9 January 2012].
28. National Center for Biotechnology Information-dbSNP, 2011. Available at: http://www.ncbi.nlm.nih.gov/snp [Accessed 9 January 2012].
29. MacLeod SL, Tang YM. The role of recently discovered genetic polymorphism in the regulation of the human CYP1A2 gene. Proc Am Assoc Cancer Res 1998; 39:396.
30. Chen D, Tian T,Wang H, Liu H, Hu Z,Wang Y, et al. Association of human aryl hydrocarbon receptor gene polymorphisms with risk of lung cancer among cigarette smokers in a Chinese population. Pharmacogenet Genomics 2009; 19:25-34.
31. Urano T, Usui T, Shiraki M, Ouchi Y, Inoue S. Association of a single nucleotide polymorphism in the constitutive androstane receptor gene with bone mineral density. Geriatr Gerontol Int 2009; 9:235-241.
32. Oliver P, Lubomirov R, Carcas A. Genetic polymorphisms of CYP1A2, CYP3A4, CYP3A5, pregnane/steroid X receptor and constitutive androstane receptor in 207 healthy Spanish volunteers. Clin Chem Lab Med 2010; 48:635-639.
33. Lubomirov R, di Iulio J, Fayet A, Colombo S, Martinez R, Marzolini C, et al. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics 2010; 20:217-230.
34. Ikeda S, Kurose K, Jinno H, Sai K, Ozawa S, Hasegawa R, et al. Functional analysis of four naturally occurring variants of human constitutive androstane receptor. Mol Genet Metab 2005; 86:314-319. (Pubitemid 41412190)
35. Lamba JK. Pharmacogenetics of the constitutive androstane receptor. Pharmacogenomics 2008; 9:71-83. (Pubitemid 351560531)
36. Lamba V, Panetta JC, Strom S, Schuetz EG. Genetic predictors of interindividual variability in hepatic CYP3A4 expression. J Pharmacol Exp Ther 2010; 332:1088-1099.
37. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene 2004; 338: 143-156. (Pubitemid 39094759)